Inventor · disambiguated record
Isabel Aznarez
Also filed as: AZNAREZ ISABEL
12 granted patents·17 pending applications·64 citations·filing 2014–2025
89Inventor score
Top patents by PatentIndex Score
29 records- 0194US11096956B2Antisense oligomers and uses thereofSTOKE THERAPEUTICS INC·Filed 2018·Granted Aug 24, 2021·11 cites·20 claims
- 0294US9976143B2Targeted augmentation of nuclear gene outputCOLD SPRING HARBOR LABORATORY·Filed 2015·Granted May 22, 2018·25 cites·42 claims
- 0391US11083745B2Antisense oligomers for treatment of autosomal dominant mental retardation-5 and Dravet SyndromeCOLD SPRING HARBOR LABORATORY·Filed 2016·Granted Aug 10, 2021·6 cites·36 claims
- 0490US11873490B2Antisense oligomers for treatment of conditions and diseasesSTOKE THERAPEUTICS INC·Filed 2020·Granted Jan 16, 2024·2 cites·19 claims
- 0590US10696969B2Targeted augmentation of nuclear gene outputCOLD SPRING HARBOR LABORATORY·Filed 2018·Granted Jun 30, 2020·4 cites·21 claims
- 0690US10683503B2Antisense oligomers for treatment of conditions and diseasesSTOKE THERAPEUTICS INC·Filed 2019·Granted Jun 16, 2020·6 cites·62 claims
- 0789US11814622B2OPA1 antisense oligomers for treatment of conditions and diseasesSTOKE THERAPEUTICS INC·Filed 2023·Granted Nov 14, 2023·1 cites·21 claims
- 0889US10913947B2Antisense oligomers for treatment of conditions and diseasesSTOKE THERAPEUTICS INC·Filed 2019·Granted Feb 9, 2021·6 cites·79 claims
- 0984US2025270563A1Targeted augmentation of nuclear gene outputCOLD SPRING HARBOR LABORATORY·Filed 2024·Application pending·0 cites
- 1081US2024150760A1Antisense oligomers for treatment of conditions and diseasesSTOKE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1179US11352624B2Reducing nonsense-mediated MRNA decayCOLD SPRING HARBOR LABORATORY·Filed 2020·Granted Jun 7, 2022·1 cites·11 claims
- 1277US10647983B2Reducing nonsense-mediated mRNA decayCOLD SPRING HARBOR LABORATORY·Filed 2014·Granted May 12, 2020·2 cites·15 claims
- 1376US2024102011A1Opa1 antisense oligomers for treatment of conditions and diseasesSTOKE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1469US12338437B2OPA1 antisense oligomers for treatment of conditions and diseasesSTOKE THERAPEUTICS INC·Filed 2021·Granted Jun 24, 2025·0 cites·20 claims
- 1569US2024033378A1Antisense oligomers for treatment of non-sense mediated rna decay based conditions and diseasesSTOKE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1668US2025059535A1Opa1 antisense oligomers for treatment of conditions and diseasesSTOKE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1768US2021108208A1Targeted augmentation of nuclear gene outputCOLD SPRING HARBOR LABORATORY·Filed 2020·Application pending·0 cites
- 1867US2024254488A1Antisense oligomers for treatment of non-sense mediated rna decay based conditions and diseasesSTOKE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1966US2024117353A1Compositions for treatment of conditions and diseases associated with polycystin expressionSTOKE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2066US2022088058A1Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndromeCOLD SPRING HARBOR LABORATORY·Filed 2021·Application pending·0 cites
- 2165US2022118000A1Antisense oligomers and uses thereofSTOKE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2259US2022290142A1Compositions and methods for modulating splicing and protein expressionSTOKE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2358US2022127612A1Methods and compositions for modulating splicing and translationSTOKE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2454US2023116704A1Antisense oligomers for treatment of conditions and diseasesSTOKE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2553US2025388902A1Antisense oligomers for treatment of non-sense mediated rna decay based conditions and diseasesSTOKE THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2653US2022162599A1Methods and compositions for modulating splicing of alternative intronsSTOKE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2752US2021268667A1Antisense oligomers for treatment of non-sense mediated rna decay based conditions and diseasesSTOKE THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2849US12060558B2Methods and compositions for treatment of cholesteryl ester storage diseaseSTOKE THERAPEUTICS INC·Filed 2019·Granted Aug 13, 2024·0 cites·18 claims
- 2944US2025243493A1Compounds for treatment of conditions and diseasesSTOKE THERAPEUTICS INC·Filed 2025·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Isabel Aznarez files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →